No content to show...
Description
HARMONIX is developing a proprietary, non-invasive platform to protect and deliver nucleic-acid therapies (ASO, mRNA, siRNA, plasmid DNA…) to the central nervous system. Today, 98% of drugs do not cross the blood-brain barrier. Our functionalizable microbubbles encapsulate and protect the therapy. Activated by focused ultrasound, they open the barrier locally and transiently, and can be re-administered. In our models, delivery efficiency is 10 times higher than that of microbubbles currently on the market. Proof of concept in glioblastoma; neurodegenerative programme underway with a pharma partner. CNRS Orléans spin-off, patent under exclusive licence, positive freedom-to-operate opinion. Licensing model by indication. i-Lab Grand Prix 2025, Servier Golden Ticket 2026.
